Double-barreled approach doubles survival times in recurrent glioma patients

Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly-appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mike Ward, Informa Pharma Intelligence insight global director of content, how his company’s approach has potential to double brain cancer survival.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Martin Duvall – CEO, Tocagen